مباشر

Endpoints NewsPost-Hoc Live: Jeremy Levin on biotech's existential moment Endpoints NewsOutlook says FDA will sign off on its version of Avastin for wet AMD BioPharma DiveEarly data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveLilly dives into vaccine research with 3 biotech buyouts FierceBiotechMakary’s FDA reforms ‘continue to move forward’ despite leadership turmoil Clinical OMICsGPS Tracking Upends Rural Uganda’s Schistosomiasis Transmission Assumptions Endpoints NewsCartesian secures funding to 'accelerate' launch; Editas sells $125M in stock Endpoints NewsCan AI do scientific research? Billions chase hopes of superintelligence BioWorldLilly buys three vaccine makers; PCSK9 base editor shows promise BioWorldChina’s new IIT rules expected to wipe out ‘gray market’BioWorldDaewoong takes over Turn Bio’s longevity platform from Hanall BioWorldTennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline

BioWorld ٢٦ مايو ٢٠٢٦

MSD divulges new KLKB1 inhibitors

Merck Sharp & Dohme LLC (MSD) has reported new plasma kallikrein (KLKB1) inhibitors potentially useful for the treatment of diabetic macular edema, cancer, here...

Merck Sharp & Dohme LLC (MSD) has reported new plasma kallikrein (KLKB1) inhibitors potentially useful for the treatment of diabetic macular edema, cancer, hereditary angioedema, uveitis, pancreatitis, arthritis, nephropathy and inflammatory disorders and among others.